Homoeopathic treatment of respiratory sequelae of post- covid cases: an open label prospective interventional pilot study

Dr Anil Khurana0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Age 18-80 years
•2.Previously positive COVID cases (ICD code: U07.1)
•3.Patient who tested to be COVID-19 negative, 4 weeks after discharge from COVID Care Centre.
•4.Patient presenting with any of the respiratory symptoms such as - shortness of breath, cough, expectoration, chest pain and other respiratory complaints (ICD code: B97.29)
•5.HRCT confirmed cases of COVID Lung Damage like ground glass opacities and fibrosis
•6.PFT with features of restriction evidenced by FVC < 80% and FeV1 < 80% of the predicted value ( ATS-ERS recommendation/ guideline)
•7.Willing to give consent in writing

•1.Patients who are tested to be COVID-19 positive, at the time of enrollment in the study.
•2.Patient with previous history of COPD, Asthma, Bronchiectesis and Chronic Cardiac ailments
•3.Pregnant and lactating women
•4.Patients who are not willing to volunteer for the study.
•5.Patients developing serious complications, Immuno-compromisedpatients
•6.Idiosyncratic reactions, severe medicinal aggravation and requiring ventilator support or emergency surgical intervention.

发起方

Dr Anil Khurana